AXGN - AxoGen Inc. (AXGN) Q1 2024 Earnings Call Transcript
2024-05-05 01:21:09 ET
AxoGen, Inc. (AXGN)
Q1 2024 Earnings Conference Call
May 02, 2024 08:00 AM ET
Company Participants
Harold Tamayo - VP, Finance and IR
Karen Zaderej - Chairman, CEO and President
Nir Naor - CFO
Conference Call Participants
Michael Sarcone - Jefferies
Mike Kratky - Leerink Partners
Caitlin Cronin - Canaccord Genuity
Ross Osborn - Cantor Fitzgerald
Presentation
Operator
Greetings, and welcome to the AxoGen, Inc. 2024 First Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. It's now my pleasure to introduce your host, Harold Tamayo, Vice President of Finance and Investor Relations. Thank you, Harold. You may begin.
Harold Tamayo
Thank you, Keith. Good morning, everyone. Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President; and Nir Naor, Chief Financial Officer. Karen will discuss the first quarter of 2024 financial results, and Nir will provide an analysis of our financial performance and guidance and discuss our outlook for the year, followed by a question-and-answer session.
Today's call is being broadcast live via webcast, which is available on the Investors section of the AxoGen's website. Following the end of the live call, a replay will be available in the Investors section of the company's website at www.axogeninc.com.
Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements, including our financial guidance, our expectations regarding our ability to expand our footprint and expand revenue from core accounts, anticipated growth for revenue categories, marketing opportunities with nerve applications associated with breast, OMF protection and surgical treatment of pain and new products; our expectations regarding the timing of the launch of Avive+; our statement regarding the timing of the complete biologics license application submission for Avance nerve graft as well as a statement regarding the timing for approval of the BLA. Our expectation is that assuming approval of the BLA, Avance nerve graft will be designated as a reference product and the expected market exclusivity of such designation and our expectations around cash flow, including that we will continue trending towards cash flow breakeven and profitability....
AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript